US 11464869
Non-adult human dosing of brentuximab vedotin
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11464869 (Non-adult human dosing of brentuximab vedotin) held by Takeda Pharmaceutical Company Limited expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61K31/475